These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 17942524)

  • 1. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
    Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
    Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.
    Marckmann S; Wiesemann E; Hilse R; Trebst C; Stangel M; Windhagen A
    Clin Exp Immunol; 2004 Dec; 138(3):499-506. PubMed ID: 15544628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis.
    Wiesemann E; Deb M; Hemmer B; Radeke HH; Windhagen A
    Clin Immunol; 2008 Sep; 128(3):306-13. PubMed ID: 18539537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b.
    Jensen MA; Yanowitch RN; Reder AT; White DM; Arnason BG
    Mult Scler; 2010 Jan; 16(1):30-8. PubMed ID: 20007427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis.
    Miyazaki Y; Iwabuchi K; Kikuchi S; Fukazawa T; Niino M; Hirotani M; Sasaki H; Onoé K
    Mult Scler; 2008 Sep; 14(8):1044-55. PubMed ID: 18573819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of CD86/CD28 and CD40/CD154 pathways in regulating monocyte-derived CD80 expression during their interaction with allogeneic endothelium.
    Wang P; Liu Z; Wu C; Zhu B; Wang Y; Xu H
    Transplant Proc; 2008 Oct; 40(8):2729-33. PubMed ID: 18929847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease.
    Trabattoni D; Saresella M; Pacei M; Marventano I; Mendozzi L; Rovaris M; Caputo D; Borelli M; Clerici M
    J Immunol; 2009 Oct; 183(8):4984-93. PubMed ID: 19794071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity.
    Frisullo G; Angelucci F; Caggiula M; Nociti V; Iorio R; Patanella AK; Sancricca C; Mirabella M; Tonali PA; Batocchi AP
    J Neurosci Res; 2006 Oct; 84(5):1027-36. PubMed ID: 16865709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism.
    Azoulay D; Mausner-Fainberg K; Urshansky N; Fahoum F; Karni A
    J Neuroimmunol; 2009 Jun; 211(1-2):114-9. PubMed ID: 19419774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
    Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
    Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
    van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
    Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
    Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
    J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
    Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
    Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
    J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
    Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
    Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis.
    Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Bornstein NM; Karni A
    J Neuroimmunol; 2011 Mar; 232(1-2):171-8. PubMed ID: 21111488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.